Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosurveillance

    Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

    By Global Biodefense StaffJune 22, 2022
    Colorized transmission electron micrograph of monkeypox virus particles (green) cultivated and purified from cell culture. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID
    Share
    Facebook LinkedIn Reddit Email

    US Expanding Monkeypox Testing Capacity as Cases Rise

    As the official count of monkeypox cases in the U.S. hit 156 this week, the Centers for Disease Control and Prevention (CDC) moved to improve its cumbersome diagnostic testing pathway by shipping orthopoxvirus tests to five commercial laboratory companies, including the nation’s largest reference laboratories.

    Clinicians previously were forced to report suspected monkeypox infections to health department officials who decide whether the cases meet criteria to undergo testing at public labs. Samples then were sent on to the CDC for confirmation. Extensive paperwork and multiple phone calls to coordinate with health officials created bottlenecks.

    Adding Commercial Laboratory Testing Capability

    The commercial laboratories will dramatically expand testing capacity nationwide and make testing more convenient and accessible for patients and health care providers. Health care providers will be able to use these laboratories (which include Aegis Science, Labcorp, Mayo Clinic Laboratories, Quest Diagnostics and Sonic Healthcare) by early July and testing capacity through these companies will be ramped up throughout the month. This development will facilitate increased testing, leverage established relationships between clinics, hospitals and commercial laboratories, and support our ability to better understand the scope of the current monkeypox outbreak. 

    “All Americans should be concerned about monkeypox cases. Thankfully we have right now the tools to fight and treat cases in America,” said Health and Human Services Secretary Xavier Becerra. “By dramatically expanding the number of testing locations throughout the country, we are making it possible for anyone who needs to be tested to do so.”

    Examples of Monkeypox Rashes. Photo credit: UK Health Security Agency

    Improving Public Health Lab Monkeypox Testing Capacity

    CDC, in collaboration with the Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services, and the HHS Office of the Assistant Secretary for Preparedness and Response has also been expanding the capacity in the Laboratory Response Network of public health labs. CDC has worked with the LRN to augment the number of public health laboratories that can perform the test to over 67 laboratories across 48 states and the number of weekly tests available within the LRN to over 8,000 tests per week. In addition to making testing more convenient and accessible through commercial laboratories, CDC will continue to work with state and local health departments to make the LRN process more efficient and reach out to health care providers and their state and local partners to learn more about monkeypox.

    In June, CDC updated and expanded the monkeypox case definition and continues to encourage health care providers to consider testing for all rashes with clinical suspicion for monkeypox. Health care providers who see a patient with a rash that resembles monkeypox or might be more characteristic of more common infections (e.g., varicella zoster, herpes zoster, or syphilis) should carefully evaluate the patient for monkeypox (see images and links) and testing should be considered.  Anyone who has risk factors for monkeypox and a new rash should seek care and testing.

    Since the United States detected its first case, FDA has worked with commercial laboratories and manufacturers to make monkeypox tests more readily available to patients and providers who need them.  FDA is working closely with CDC to increase production of its FDA-cleared test. FDA is concurrently exercising enforcement discretion regarding CDC’s tests, which permits hospitals to develop their own high-quality laboratory developed tests beyond the current LRN. CDC has published its FDA-approved testing protocol for any interested laboratory to use to begin testing for monkeypox. FDA has also authorized the use of additional reagents and automation to increase the testing capacity of laboratories using the CDC test.

    Sources: HHS

    Editor Pick Emerging Threats Epidemiology mpox Poxviruses
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleUK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
    Next Article Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.